Schema of ECOG trial E1900. Patients in remission after induction therapy were allocated based on risk factors (as defined in “Treatment”). The autologous consolidation randomization to gemtuzumab ozogamicin was closed in October 2007. Eligibility requirements for autologous HCT are given in “Treatment.” HiDAC indicates high-dose cytarabine.